Justin Hartke is a Gastroenterology physician affiliated with Indiana University Health. OpenAlex indexes 20 publications with 1,219 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
411 Westwood Dr
Wausau, WI 54401
Telephone
715-847-2558Registry record last updated 3 Jul 2018.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- NESTLE HEALTHCARE NUTRITION INC.Program year20233 payments
- Regeneron Healthcare Solutions, Inc.Program year20231 payment
- ABBVIE INC.Program year20223 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
43.4%TNF inhibitor40.8%Infliximab100%Part B, office-administered≥11 patientsInterleukin-12 Antagonist2.5%Stelara100%Part D<11 patientsMetabolism & gastrointestinal
42.5%Proton pump inhibitor20.2%Omeprazole65%Pantoprazole Sodium35%Part D≥94 patientsGuanylate Cyclase-C Agonist4.6%Linzess100%Part D≥21 patients+ 10 more classes in this area
Cardiovascular
8.2%Bile Acid Sequestrant6.1%Colestipol Hcl68%Cholestyramine17%Cholestyramine Light15%Part D<11 patientsLoop diuretic0.9%Furosemide100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
The American Journal of Gastroenterology
2018 - Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases
Clinical Gastroenterology and Hepatology
2018 - Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases
2018 - Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
The American Journal of Gastroenterology
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Douglas Zipes, MD
Indiana University Health
Lawrence Einhorn, MD
Indiana University Health
Lisa Landrum, MD
Indiana University Health
Patrick Loehrer, MD
Indiana University Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”